BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hitchcock KE, Nichols RC, Morris CG, Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA, Zaiden RA, Mendenhall NP, Rutenberg MS. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World J Gastrointest Surg 2017; 9(4): 103-108 [PMID: 28503258 DOI: 10.4240/wjgs.v9.i4.103]
URL: https://www.wjgnet.com/1948-9366/full/v9/i4/103.htm
Number Citing Articles
1
Sarah Stefanowicz, Kristin Stützer, Sebastian Zschaeck, Annika Jakobi, Esther G. C. Troost. Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancerRadiation Oncology 2018; 13(1) doi: 10.1186/s13014-018-1165-0
2
Nobuhiro Tsuchiya, Ryusei Matsuyama, Takashi Murakami, Yasuhiro Yabushita, Yu Sawada, Takafumi Kumamoto, Itaru Endo. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long‐Term ChemotherapyWorld Journal of Surgery 2020; 44(8): 2752 doi: 10.1007/s00268-020-05503-4
3
Jana M. Kobeissi, Charles B. Simone, Haibo Lin, Lara Hilal, Carla Hajj. Proton Therapy in the Management of Pancreatic CancerCancers 2022; 14(11): 2789 doi: 10.3390/cancers14112789
4
Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology 2024; 47(4): 185 doi: 10.1097/COC.0000000000001076
5
Mikaela Dell’Oro, Michala Short, Puthenparampil Wilson, Eva Bezak. Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic CancerCancers 2020; 12(1): 163 doi: 10.3390/cancers12010163
6
Yanming Zhou, Shan Liao, Jun You, Huaxing Wu. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literatureUpdates in Surgery 2022; 74(1): 43 doi: 10.1007/s13304-021-01089-1
7
Toshimichi ASANO, Satoshi HIRANO, Toru NAKAMURA, Takehiro NOJI, Keisuke OKAMURA, Takahiro TSUCHIKAWA, Yuma EBIHARA, Toshiaki SHICHINOHE. Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancerSuizo 2018; 33(1): 48 doi: 10.2958/suizo.33.48
8
Romaine Charles Nichols, Michael Rutenberg. Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protonsWorld Journal of Gastrointestinal Surgery 2019; 11(7): 303-307 doi: 10.4240/wjgs.v11.i7.303
9
Toshimichi Asano, Satoshi Hirano, Toru Nakamura, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatmentJournal of Hepato-Biliary-Pancreatic Sciences 2018; 25(7): 342 doi: 10.1002/jhbp.565
10
William G. Breen, Krishan R. Jethwa, Nathan Y. Yu, Grant M. Spears, William S. Harmsen, Robert C. Miller, Jonathan B. Ashman, William G. Rule, Terence T. Sio, Michelle A. Neben-Wittich, Michael G. Haddock, Amit Mahipal, Mark J. Truty, Christopher L. Hallemeier, Kenneth W. Merrell. Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry StudyPractical Radiation Oncology 2021; 11(1): e63 doi: 10.1016/j.prro.2020.06.011